Another trial (phase 3, CheckMate-649) evaluated Nivolumab (PD-1 inhibitor) in combination with chemotherapy versus chemotherapy alone for patients with GEJ, EAC, gastric cancer (HER2 negative), supporting an improved OS [64]. The gene discussed is PDCD1; the disease is gastric cancer.